TABLE 1.
Patients’ characteristics during the two periods
| ‘Period 1’ | ‘Period 2’ | Evolution rate (%) | p‐value | |
|---|---|---|---|---|
| Number of patients (n,%) | 365 | 473 | 30 | |
| New patients | 62 (17.0) | 159 (33.6) | 156 | 0.01 |
| Adults | 354 (97.0) | 452 (95.6) | 27,7 | ns |
| Sex (Female) | 168 (46.0) | 260 (55.0) | 54,8 | 0.01 |
| Age (median, IQR) | ||||
| Adults | 73 [64;79] | 72 [60;78] | / | 0.01 |
| Children | 10 [3;11] | 4 [3;11] | ns | |
| Haematological malignancy (n,%) | 343 (94.0) | 374 (79.1) | 9 | 0.01 |
| MM | 126 (34.5) | 150 (31.7) | 19 | 0.05 |
| AML and MDS | 172 (47.1) | 172 (36.4) | 0 | |
| ALL | 11 (3) | 26 (5.5) | 136 | |
| NHL and Hodgkin disease | 34 (9.3) | 26 (5.5) | −23.5 | |
| Solid tumour (n,%) | 22 (6.0) | 99 (20.9) | 350 | 0.01 |
| Breast cancer | 16 (4.4) | 86 (18.2) | 437 | 0.1 |
| NSCLC and Others | 6 (1.6) | 13 (2.7) | 117 | |
IQR, Interquartile range [+25%‐+75%]; ns, non‐significant; MM, multiple myeloma; AML, acute myeloid leukaemia; MDS, Myelodysplastic syndrome; ALL, Acute lymphoblastic leukaemia; NHL, Non‐Hodgkin lymphoma; NSCLC, non‐small cell lung cancer; Others, sarcoma, glioblastoma, melanoma, bladder cancer.